Total Funding
1
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
4267419
Three Rivers Pharmaceuticals develops, manufactures, and markets generic pharmaceutical drug products.
Acquired by 
Kadmon
Eric R. Sprys: CFO- Don Kerrish: President & CEO
About the Company
Three Rivers Pharmaceuticals, LLC develops, manufactures, and markets generic pharmaceutical drug products in the United States and internationally. It offers prescription drugs in the therapeutic categories of antiviral and antifungal agents. The company’s products include AMPHOTEC for the treatment of invasive aspergillosis, a systemic fungal
infection; and INFERGEN, RIBASPHERE tablets, RIBASPHERE capsules, and RibaPak tablets for the treatment of hepatitis C. It also markets Topotecan Hydrochloride for injection. Three Rivers Pharmaceuticals, LLC was founded in 2000 and is based in Warrendale, Pennsylvania. As of October 25, 2010, Three Rivers Pharmaceuticals, LLC operates as a subsidiary of Kadmon Pharmaceuticals LLC.
